Analysts think CRMD stock price could increase by 71%
Feb 09, 2025, 12:25 PM
5.66%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
7 analysts think CRMD stock price will increase by 70.67%. The current median analyst target is $17.34 compared to a current stock price of $10.16. The lowest analysts target is $12.12 and the highest analyst target is $19.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
